Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06880081 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 28, 2025 to Feb 27, 2026
    • Study completion date: Oct 28, 2025 to Apr 28, 2026
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 treatment? Participants will * Receive one subcutaneous injection of PN20 according to weight; * Visit the clinic for assessment.
Trial Details
NCT Number NCT06880081
Lead Sponsor Chongqing Peg-Bio Biopharm Co., Ltd.
Conditions
(from sponsor)		 Primary Immune Thrombocytopenia (ITP)
Related terms Purpura, Thrombocytopenic, Idiopathic
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov